financetom
Business
financetom
/
Business
/
Kadant Q2 revenue beats expectations, maintains annual revenue, profit guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kadant Q2 revenue beats expectations, maintains annual revenue, profit guidance
Jul 29, 2025 1:53 PM

Overview

* Kadant ( KAI ) Q2 rev falls 7% yr/yr but beats analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus despite 18% decline, per LSEG data

* Co's bookings rise 7% to $269 mln

Outlook

* Kadant ( KAI ) expects 2025 revenue of $1.020 bln to $1.040 bln

* Kadant ( KAI ) maintains 2025 adjusted EPS guidance of $9.05 to $9.25

* Kadant sees Q3 2025 revenue of $256 mln to $263 mln

* Company expects stable demand for aftermarket parts to continue

* Co expectsstronger" bookings in the second half of 2025

Result Drivers

* BOOKINGS GROWTH - Co attributes 7% increase in bookings to customer preference for its equipment and technologies, per CEO Jeffrey Powell

* CASH FLOW IMPROVEMENT - Operating cash flow rose 44% and free cash flow increased 58%, indicating efficient operational management

* GROSS MARGIN INCREASE - Gross margin improved by 150 basis points to 45.9%, reflecting better cost management

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $255 mln $250.40

Revenue mln (4

Analysts

)

Q2 Beat $2.31 $2.08 (4

Adjusted Analysts

EPS )

Q2 EPS $2.22

Q2 Net $26 mln

Income

Q2 Beat $52 mln $49.20

Adjusted mln (4

EBITDA Analysts

)

Q2 Gross 45.9%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for Kadant Inc ( KAI ) is $327.50, about 5% below its July 28 closing price of $344.02

* The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved